SCHEMBL328780

SCHEMBL328780

[c]1c(Oc2ccccc2)ccc2ccccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 5/20 0.42
TSHR P16473 1/20 0.42
KDM4E B2RXH2 1/20 0.38
GLA P06280 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
HTT P42858 2/20 0.35
ALDH1A1 P00352 1/20 0.35
NR1H2 P55055 1/20 0.34
BAX Q07812 1/20 0.34
MAOA P21397 1/20 0.34
PGR P06401 2/20 0.32
MAOB P27338 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
POLB P06746 1/20 0.30
CYSLTR2 Q9NS75 1/20 0.30
CYSLTR1 Q9Y271 1/20 0.30
LMNA P02545 1/20 0.30
KDM1A O60341 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20524986 0.87 CYP2A6 (0.32) TSHRALDH1A1
SCHEMBL8130656 0.85 CYP2A6 (0.39) LTA4HTSHRKDM4EMAPTALDH1A1
SCHEMBL328940 0.85 LTA4H (0.39) LTA4HTSHRKDM4EGLAMAPT
SCHEMBL8125384 0.81
SCHEMBL8124707 0.81 LMNA (0.46) LTA4HKMT2AHTTALDH1A1LMNA
SCHEMBL328744 0.80 HPRT1 (0.42) LTA4HTSHRKDM4EGLAMAPT
SCHEMBL3237917 0.79 CA1 (0.30) CA1CA2
SCHEMBL15874755 0.78
SCHEMBL4720994 0.76 RAB9A (0.38) TSHRKDM4EMAPTKMT2AHTT
SCHEMBL6538521 0.75 KCNA3 (0.52) LTA4HALDH1A1CYSLTR2CYSLTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115385956-A Biaryl diphosphine ligands and transition metal complexes thereof 东莞市均成高新材料有限公司 2022-11-25 CN claimed
CN-115385957-A Linear terphenyl aryl phosphine ligand and transition metal complex thereof 东莞市均成高新材料有限公司 2022-11-25 CN claimed
CN-115385955-A Tetrabiarylphosphine ligands and transition metal complexes thereof 东莞市均成高新材料有限公司 2022-11-25 CN claimed
CN-115181128-A Phosphine ligand of arylmethyl biaryl and transition metal complex thereof 东莞市均成高新材料有限公司 2022-10-14 CN claimed
US-8900725-B2 Dendrimer and organic light-emitting device using the same SAMSUNG DISPLAY CO., LTD. 2014-12-02 US claimed
US-8865322-B2 Dendrimer and organic light-emitting device using the same SAMSUNG DISPLAY CO., LTD. (KR) 2014-10-21 US claimed
EP-2407501-B1 Dendrimer and organic light-emitting device using the same SAMSUNG DISPLAY CO LTD (KR) 2013-09-11 EP claimed
EP-2407502-B1 Dendrimer and organic light-emitting device using the same SAMSUNG DISPLAY CO LTD (KR) 2013-06-19 EP claimed
CN-102432844-A Dendrimer and organic light-emitting device using the same SAMSUNG MOBILE DISPLAY CO LTD 2012-05-02 CN claimed
CN-102372662-A Dendrimer and organic light-emitting device using the same SAMSUNG MOBILE DISPLAY CO LTD 2012-03-14 CN claimed
EP-1921082-A1 Silanylamine-based compound, method of preparing the same and organic light emitting device including organic layer comprising the silanylamine-based compound Samsung SDI Co., Ltd. (KR) 2008-05-14 EP claimed
US-20080106188-A1 SILANYLAMINE-BASED COMPOUND, METHOD OF PREPARING THE SAME AND ORGANIC LIGHT EMITTING DEVICE INCLUDING ORGANIC LAYER COMPRISING THE SILANYLAMINE-BASED COMPOUND SAMSUNG DISPLAY CO., LTD. (KR) 2008-05-08 US claimed
US-6723718-B2 GLUTAMATERGIC ANTAGONIST AND AGONISTS; ANTIISCHEMIC AND ANTISPASMODIC AGENTS; BRAIN AND NERVOUS SYSTEM DISORDERS; TRAUMA BAYER AKTIENGESELLSCHAFT (DE) 2004-04-20 US claimed
US-20030158424-A1 Substituted alpha, beta-anellated butyrolactones STOLLE ANDREAS (DE) 2003-08-21 US claimed
US-6462074-B1 Substituted α, β-anellated butyrolactones BAYER AKTIENGESELLSCHAFT (DE) 2002-10-08 US claimed
EP-1047684-B1 SUBSTITUTED ALPHA,BETA-ANELLATED BUTYROLACTONES BAYER AG (DE) 2002-10-02 EP claimed
US-6376539-B1 ANTIISCHEMIC AGENTS, CENTRAL NERVOUS SYSTEM DISORDERS BAYER AKTIENGESELLSCHAFT (DE) 2002-04-23 US claimed
EP-1047684-A1 SUBSTITUTED ALPHA,BETA-ANELLATED BUTYROLACTONES BAYER AG (DE) 2000-11-02 EP claimed
WO-1999036416-A1 SUBSTITUTED α,β-ANELLATED BUTYROLACTONES BAYER AKTIENGESELLSCHAFT (DE) 1999-07-22 WO claimed
US-4675316-A FUNGICIDES ROHM AND HAAS COMPANY (US) 1987-06-23 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080106188-A1 SILANYLAMINE-BASED COMPOUND, METHOD OF PREPARING THE SAME AND ORGANIC LIGHT EMITTING DEVICE INCLUDING ORGANIC LAYER COMPRISING THE SILANYLAMINE-BASED COMPOUND ICMT, SLC43A1, SLC7A5 LTA4H 174/4885TSHR 4750/4885KDM4E 2673/4885
US-20030158424-A1 Substituted alpha, beta-anellated butyrolactones GABRB2, GABRB3, GABRB1 LTA4H 1328/4885TSHR 4561/4885KDM4E 3559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.